ArticleCancer diagnosis & prognosis
Efficacy of Durvalumab-Tremelimumab Treatment in Combination With Locoregional Therapy in Unresectable Hepatocellular Carcinoma: A Preliminary Study.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Protein Induced by Vitamin K Absence or Antagonist II in Primary Liver Cancer: Basic Research Insights and Clinical Applications.Journal of clinical and translational hepatology · 2025Review
- Log-transformed α-Fetoprotein andIn vivo (Athens, Greece)Article
- The Prognostic Role of Inflammation on Hepatocellular Carcinoma.Cancer diagnosis & prognosisArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: Systemic therapy with immune checkpoint inhibitors for advanced hepatocellular carcinoma (HCC) treatment has demonstrated high response rates. Durvalumab plus tremelimumab (Dur/Tre) has been approved for HCC treatment and has become a first-line systemic therapy along with atezolizumab plus bevacizumab. However, there is early withdrawal owing to immune-related adverse effects, while others required sequential therapy owing to the lack of early therapeutic effects. Herein, we investigated the clinical characteristics of patients with progressive disease (PD) who were treated with Dur/Tre in addition to locoregional therapy. Patients and Methods: We retrospectively evaluated eight patients with HCC, who were treated with Dur/Tre in March 2025 and continued Dur/Tre until PD was treated with locoregional therapy. Additionally, immunological changes, and treatment efficacy during continuation therapy were also assessed. Treatment efficacy was evaluated using modified Response Evaluation Criteria in Solid Tumors (mRECIST). Results: At Dur/Tre induction, patients (mean age, 76.88 years, all male) had alcoholic liver disease (n=3), nonalcoholic steatohepatitis (n=4), or hepatitis B virus (n=1). Six patients received Dur/Tre as first-line therapy, two were treated with atezolizumab plus bevacizumab as pretreatment, and the mean number of Dur/Tre cycles was 5.2. Neutrophil to lymphocyte ratio (NLR) was 2.14±1.51 at the time of Dur/Tre induction and worsened to 2.80±1.91 at the time of PD but significantly improved to 2.08±1.14 after locoregional therapy ( Conclusion: Continued Dur/Tre therapy may be effective in patients with improved NLR and DCP levels after adjunct locoregional therapy. Further studies involving larger patient cohort might determine strategic addition of locoregional therapy in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.